Please wait a minute...
Journal of Neurorestoratology  2015, Vol. 3 Issue (1): 109-114    doi: 10.2147/JN.S74145
Review     
Clinical neurorestorative progress in amyotrophic lateral sclerosis
Lin Chen1,2,5, Hongyun Huang3, Haitao Xi4,5, Gengsheng Mao3
1Medical Center, Tsinghua University,;
2Tsinghua University Yuquan Hospital,;
3General Hospital of Chinese People's Armed Police Forces,;
4Beijing Rehabilitation Hospital of Capital Medical University,;
5Beijing Hongtianji Neuroscience Academy, Beijing, People's Republic of China
Download: PDF (178 KB)     
Export: BibTeX | EndNote (RIS)      

Abstract  Amyotrophic lateral sclerosis is a progressive and fatal neurodegenerative disease characterized by progressive paralysis and motor neuron death. In addition to symptomatic managements such as ventilation and nutritional support, neurorestorative therapies have demonstrated anti-neurodegenerative potential and may improve quality of life for patients. Currently, clinical neurorestorative strategies include pharmacological management (granulocyte colony stimulating factor), neuromodulatory intervention (repetitive transcranial magnetic and cortical stimulation), cell transplantation (bone marrow stromal cells, olfactory ensheathing cells, granulocyte colony stimulating factor-mobilized peripheral blood stromal cells, hematopoietic stem and progenitor cells, neural stem/progenitor cells, CD133+ cells and CD34+ cells), bioengineering and tissue engineering therapy, and combined neurorehabilitative treatment. In this review, we describe the latest progress in clinical neurorestorative management of amyotrophic lateral sclerosis and discuss the underlying evidence base.

Key wordsamyotrophic lateral sclerosis      neurorestorative treatment      cell transplantation      clinical trial     
Published: 26 December 2015
Corresponding Authors: Lin Chen, Tsinghua University Yuquan Hospital, 5 Shijingshan Road, Beijing, Republic of China, Email chenlin_china@163.com, Hongyun Huang General Hospital of Chinese People's Armed Police Forces, 69 Yongding Road, Haidian District, Beijing, People's Republic of China, Email hongyunh@gmail.com   
Cite this article:

Lin Chen, Hongyun Huang, Haitao Xi, Gengsheng Mao. Clinical neurorestorative progress in amyotrophic lateral sclerosis. Journal of Neurorestoratology, 2015, 3: 109-114.

URL:

http://jnr.tsinghuajournals.com/10.2147/JN.S74145     OR     http://jnr.tsinghuajournals.com/Y2015/V3/I1/109

1. Sejvar JJ, Holman RC, Bresee JS, Kochanek KD, Schonberger LB.Amyotrophic lateral sclerosis mortality in the United States, 1979-2001.Neuroepidemiology. 2005;25:144-152.
2. Worms PM.The epidemiology of motor neuron diseases: a review of recent studies.J Neurol Sci. 2001;191:3-9.
3. Haverkamp LJ, Appel V, Appel SH.Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction.Brain. 1995;118:707-719.
4. Rosen DR, Siddique T, Patterson D, et al.Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.Nature. 1993;362:59-62.
5. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW.Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis.Ann Neurol. 1995;38:73-84.
6. Ferrante RJ, Browne SE, Shinobu LA, et al.Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis.J Neurochem. 1997;69:2064-2074.
7. Smith RG, Henry YK, Mattson MP, Appel SH.Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis.Ann Neurol. 1998;44:696-699.
8. Ro LS, Lai SL, Chen CM, Chen ST.Deleted 4977-bp mitochondrial DNA mutation is associated with sporadic amyotrophic lateral sclerosis: a hospital-based case-control study.Muscle Nerve. 2003;28:737-743.
9. Reid E, Kloos M, Ashley-Koch A, et al.A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10).Am J Hum Genet. 2002;71:1189-1194.
10. Hirano A, Donnenfeld H, Sasaki S, Nakano I.Fine structural observations of neurofilamentous changes in amyotrophic lateral sclerosis.J Neuropathol Exp Neurol. 1984;43:461-470.
11. Hirano A, Nakano I, Kurland LT, Mulder DW, Holley PW, Saccomanno G.Fine structural study of neurofibrillary changes in a family with amyotrophic lateral sclerosis.J Neuropathol Exp Neurol. 1984;43:471-480.
12. Carpenter S.Proximal axonal enlargement in motor neuron disease.Neurology. 1968;18:841-851.
13. Miller RG, Jackson CE, Kasarskis EJ, et al.Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology. 2009;73:1218-1226.
14. Miller RG, Jackson CE, Kasarskis EJ, et al.Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology. 2009;73:1227-1233.
15. Zoccolella S, Santamato A, Lamberti P.Current and emerging treatments for amyotrophic lateral sclerosis.Neuropsychiatr Dis Treat. 2009;5:577-595.
16. Boll MC, Bayliss L, Vargas-Cañas S, et al.Clinical and biological changes under treatment with lithium carbonate and valproic acid in sporadic amyotrophic lateral sclerosis.J Neurol Sci. 2014;340:103-108.
17. Verstraete E, Veldink JH, Huisman MH, et al.Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial.J Neurol Neurosurg Psychiatry. 2012;83:557-564.
18. Gianforcaro A, Hamadeh MJ.Vitamin D as a potential therapy in amyotrophic lateral sclerosis.CNS Neurosci Ther. 2014;20:101-111.
19. Grassinger J, Khomenko A, Hart C, et al.Safety and feasibility of long term administration of recombinant human granulocyte-colony stimulating factor in patients with amyotrophic lateral sclerosis.Cytokine. 2014;67:21-28.
20. Di Lazzaro V, Dileone M, Pilato F, et al.Repetitive transcranial magnetic stimulation for ALS. A preliminary controlled study.Neurosci Lett. 2006;408:135-140.
21. Di Lazzaro V, Pilato F, Profice P, et al.Motor cortex stimulation for ALS: a double blind placebo-controlled study.Neurosci Lett. 2009;464:18-21.
22. Zanette G, Forgione A, Manganotti P, Fiaschi A, Tamburin S.The effect of repetitive transcranial magnetic stimulation on motor performance, fatigue and quality of life in amyotrophic lateral sclerosis.J Neurol Sci. 2008;270:18-22.
23. Sidoti C, Agrillo U.Chronic cortical stimulation for amyotrophic lateral sclerosis: a report of four consecutive operated cases after a 2-year follow-up: technical case report.Neurosurgery. 2006;58:E384.
24. Orient-Lopez F, Terre-Boliart R, Guevara-Espinosa D, Bernabeu- Guitart M.Neurorehabilitation treatment of amyotrophic lateral sclerosis.Rev Neurol. 2006;43:549-555.
25. Lewis M, Rushanan S.The role of physical therapy and occupational therapy in the treatment of amyotrophic lateral sclerosis.NeuroRehabilitation. 2007;22:451-461.
26. Kühnlein P, Gdynia HJ, Sperfeld AD, et al.Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis.Nat Clin Pract Neurol. 2008;4:366-374.
27. Sanjak M, Bravver E, Bockenek WL, Norton HJ, Brooks BR.Supported treadmill ambulation for amyotrophic lateral sclerosis: a pilot study.Arch Phys Med Rehabil. 2010;91:1920-1929.
28. Arbesman M, Sheard K.Systematic review of the effectiveness of occupational therapy-related interventions for people with amyotrophic lateral sclerosis.Am J Occup Ther. 2014;68:20-26.
29. Cordes AL, Jahn K, Hass R, et al.Intramedullary spinal cord implantation of human CD34(+) umbilical cord-derived cells in ALS.Amyotroph Lateral Scler. 2011;12:325-330.
30. Lunn JS, Hefferan MP, Marsala M, Feldman EL.Stem cells: comprehensive treatments for amyotrophic lateral sclerosis in conjunction with growth factor delivery.Growth Factors. 2009;27:133-140.
31. Sun H, Bénardais K, Stanslowsky N, et al.Therapeutic potential of mesenchymal stromal cells and MSC conditioned medium in amyotrophic lateral sclerosis (ALS) - in vitro evidence from primary motor neuron cultures, NSC-34 cells, astrocytes and microglia.PLoS One. 2013;8:e72926.
32. Connick P, Chandran S.Mesenchymal stromal cell transplantation modulates neuroinflammatory milieu in amyotrophic lateral sclerosis.Cytotherapy. 2014;16:1031-1032.
33. Mazzini L, Fagioli F, Boccaletti R, et al.Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans.Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:158-161.
34. Mazzini L, Mareschi K, Ferrero I, et al.Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis.Neurol Res. 2006;28:523-526.
35. Mazzini L, Mareschi K, Ferrero I, et al.Stem cell treatment in amyotrophic lateral sclerosis.J Neurol Sci. 2008;265:78-83.
36. Mazzini L, Ferrero I, Luparello V, et al.Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a Phase I clinical trial.Exp Neurol. 2010;223:229-237.
37. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al.Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.Arch Neurol. 2010;67:1187-1194.
38. Cho GW, Noh MY, Kim HY, Koh SH, Kim KS, Kim SH.Bone marrow-derived stromal cells from amyotrophic lateral sclerosis patients have diminished stem cell capacity.Stem Cells Dev. 2010;19:1035-1042.
39. Bossolasco P, Cova L, Calzarossa C, et al.Metalloproteinase alterations in the bone marrow of ALS patients.J Mol Med (Berl). 2010;88:553-564.
40. Martínez HR, Marioni SS, Escamilla Ocañas CE, Gonzalez Garza MT, Moreno-Cuevas JE.Amyotrophic lateral sclerosis in pregnancy: clinical outcome during the post-partum period after stem cell transplantation into the frontal motor cortex.Cytotherapy. 2014;16:402-405.
41 41. Huang H, Chen L, Xi H, et al. [Olfactory ensheathing cells transplantation for central nervous system diseases in1255 patients]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2009;23:14-20. Chinese.
42. Chen L, Huang H, Xi H, et al.Intracranial transplant of olfactory ensheathing cells in children and adolescents with cerebral palsy: a randomized controlled clinical trial.Cell Transplant. 2010;19:185-191.
43 43. Chen L, Huang H, Zhang J, et al. [Short-term outcome of olfactory ensheathing cells transplantation for treatment of amyotrophic lateral sclerosis]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi.2007;21:961-966. Chinese.
44 44. Huang H, Tan K, Chen L, et al. [MR spectroscopy evaluation and short-term outcome of olfactory ensheathing cells transplantation in amyotrophic lateral sclerosis patients]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi.2007;21:52-57. Chinese.
45. Huang H, Chen L, Xi H, et al.Fetal olfactory ensheathing cells transplantation in amyotrophic lateral sclerosis patients: a controlled pilot study.Clin Transplant. 2008;22:710-718.
46. Chen L, Chen D, Xi H, et al. Olfactory ensheathing cell neurorestorotherapy for amyotrophic lateral sclerosis patients: benefits from multiple transplantations. Cell Transplant.2012;21 Suppl 1:S65-S77.
47. Cashman N, Tan LY, Krieger C, et al.Pilot study of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells in amyotrophic lateral sclerosis (ALS).Muscle Nerve. 2008;37:620-625.
48. Appel SH, Engelhardt JI, Henkel JS, et al.Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis.Neurology. 2008;71:1326-1334.
49. Deda H, Inci MC, Kürekçi AE, et al.Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up.Cytotherapy. 2009;11:18-25.
50. Martinez HR, Gonzalez-Garza MT, Moreno-Cuevas JE, Caro E, Gutierrez-Jimenez E, Segura JJ.Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients.Cytotherapy. 2009;11:26-34.
51. Riley J, Federici T, Polak M, et al.Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I safety trial, technical note, and lumbar safety outcomes.Neurosurgery. 2012;71:405-416.
52. Riley J, Glass J, Feldman EL, et al.Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I trial, cervical microinjection, and final surgical safety outcomes.Neurosurgery. 2014;74:77-87.
53. Feldman EL, Boulis NM, Hur J, et al.Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes.Ann Neurol. 2014;75:363-373.
54. Aebischer P, Pochon NA, Heyd B, et al.Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF.Hum Gene Ther. 1996;7:851-860.
55. Aebischer P, Schluep M, Deglon N, et al.Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients.Nat Med. 1996;2:696-699.
56. Zurn AD, Henry H, Schluep M, et al.Evaluation of an intrathecal immune response in amyotrophic lateral sclerosis patients implanted with encapsulated genetically engineered xenogeneic cells.Cell Transplant. 2000;9:471-484.
57. Ramón-Cueto A, Avila J.Olfactory ensheathing glia: properties and function.Brain Res Bull. 1998;46:175-187.
58. Li Y, Bao J, Khatibi NH, et al.Olfactory ensheathing cell transplantation into spinal cord prolongs the survival of mutant SOD1 (G93A) ALS rats through neuroprotection and remyelination.Anat Rec (Hoboken). 2011;294:847-857.
59. Li Y, Chen L, Zhao Y, et al. Intracranial transplant of olfactory ensheathing cells can protect both upper and lower motor neurons in amyotrophic lateral sclerosis. Cell Transplant.2013;22 Suppl 1:S51-S65.
60. Zhao CP, Zhang C, Zhou SN, et al.Human mesenchymal stromal cells ameliorate the phenotype of SOD1-G93A ALS mice. Cytotherapy. 2007;9:414-426.
61. Vercelli A, Mereuta OM, Garbossa D, et al.Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis.Neurobiol Dis. 2008;31:395-405.
62. Dileone M, Profice P, Pilato F, et al.Repetitive transcranial magnetic stimulation for ALS.CNS Neurol Disord Drug Targets. 2010;9:331-334.
63. Goyal NA, Mozaffar T.Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs.Expert Opin Investig Drugs. 2014;23:1-11.
[1] Chao Chen, Qingfa Chen, Yan Liu, Chongyang Zhang, Kaixiang Zhu, Xue Li, Haitao Xie, Rui Zhang. The cell repair research for Parkinson’s disease: A systematic review[J]. Journal of Neurorestoratology, 2020, 8(2): 93-103.
[2] Nanlin Shi, Liping Wang, Yonghao Chen, Xinyi Yan, Chen Yang, Yijun Wang, Xiaorong Gao. Steady-state visual evoked potential (SSVEP)-based brain–computer interface (BCI) of Chinese speller for a patient with amyotrophic lateral sclerosis: A case report[J]. Journal of Neurorestoratology, 2020, 8(1): 40-52.
[3] Miaomiao Zhuang, Qingheng Wu, Feng Wan, Yong Hu. State-of-the-art non-invasive brain–computer interface for neural rehabilitation: A review[J]. Journal of Neurorestoratology, 2020, 8(1): 12-25.
[4] Zhenrong Zhang, Fangyong Wang, Mingjie Song. The cell repair research of spinal cord injury: a review of cell transplantation to treat spinal cord injury[J]. Journal of Neurorestoratology, 2019, 7(2): 55-62.
[5] Lin Chen, Wise Young, Gustavo A. Moviglia, Ziad M. Al Zoubi. Summary report of the 11th Annual Conference of International Association of Neurorestoratology (IANR)[J]. Journal of Neurorestoratology, 2019, 7(1): 1-7.
[6] Zhongju Shi, Zhijian Wei, Shiqing Feng, Gustavo Moviglia, Lin Chen, Ping Wu. Highlights for the 10th Annual Conference of the International Association of Neurorestoratology[J]. Journal of Neurorestoratology, 2018, 6(1): 84-87.
[7] Andrey S. Bryukhovetskiy. Translational experience of 28 years of use of the technologies of regenerative medicine to treat complex consequences of the brain and spinal cord trauma: Results, problems and conclusions[J]. Journal of Neurorestoratology, 2018, 6(1): 99-114.
[8] Lin Chen, Yuqi Zhang, Xijing He, Saberi Hooshang. Comparison of intramedullary transplantation of olfactory ensheathing cell for patients with chronic complete spinal cord injury worldwide[J]. Journal of Neurorestoratology, 2018, 6(1): 146-151.
[9] Lin Chen, Yaping Feng, Yuqi Zhang, Hongyun Huang, Xiaodong Guo. Multicenter, randomized, double-blind placebo-control intramedullary decompression for acute complete spinal cord contusion injury[J]. Journal of Neurorestoratology, 2018, 6(1): 165-170.
[10] Feng Zhang, Xiangzhi Meng, Fang Lu, Aixian Liu, Hongyun Huang. Olfactory ensheathing cell transplantation for a patient with chronic sciatic nerve injury[J]. Journal of Neurorestoratology, 2017, 5(1): 1-4.
[11] Lin Chen, Haitao Xi, Juan Xiao, Feng Zhang, Di Chen, Hongyun Huang. Chromaffin cell transplantation for neuropathic pain after spinal cord injury: a report of two cases[J]. Journal of Neurorestoratology, 2017, 5(1): 47-50.
[12] Weston Miller. Stem cell-transplantation therapy for adrenoleukodystrophy: current perspectives[J]. Journal of Neurorestoratology, 2017, 5(1): 5-19.
[13] Mitsuhiro Enomoto. Therapeutic effects of neurotrophic factors in experimental spinal cord injury models[J]. Journal of Neurorestoratology, 2016, 4(1): 15-22.
[14] Haitao Xi, Di Chen. Cell-based neurorestorative therapy for postpoliomyelitis syndrome: a case report[J]. Journal of Neurorestoratology, 2016, 4(1): 45-50.
[15] Huiling Huang, Lin Chen, Hongyun Huang. Clinical neurorestorative progress in traumatic brain injury[J]. Journal of Neurorestoratology, 2015, 3(1): 57-62.